Evommune, Inc.

NYSE:EVMN

Biotechnology

Healthcare
$7.02 -0.82%

-$0.17 today

Market cap
$290.28M
Beta
0.10
P/E (TTM)
-9.1
EPS (TTM)
-$2.26
52W Low $13.89High $33.20

Volume 0.90M

Average 0.38M

EVMN EBITDA Margin

EBITDA as a percentage of revenue.

Evommune, Inc.NYSE: EVMN

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Context

  • EBITDA Margin widened in 1 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -1886.5% for the fiscal year ending Dec 2026, down from -519.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-519.1%+416.4 pp YoY
LTMMar 2026
-746.2%— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+416.4 pp-1367.4 pp-1783.8 pp
3 years—-379.4 pp—
5 years+210.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-519.1%
Year-over-year change
+416.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How EVMN compares with its peers on the latest reported figures

  • EVMN's LTM Mar 2026 EBITDA Margin of -746.2% is the 7th highest of the 8 companies compared; the peer median is -28.2%.
EVMN Competitors Peer median
EBITDA Margin for EVMN and competitors
Company Period LTM level YoY 3-year change
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202694.3% +118.8 pp+30.5 pp
ZYMEZymeworks Inc.LTM Sep 202621.5% +61.6 pp-99.3 pp
FTREFortrea Holdings Inc.LTM Jun 20263.0% +34.4 pp-39.8 pp
CDXSCodexis, Inc.LTM Mar 2026-28.2% +91.2 pp-29.1 pp
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026-97.9% -84.1 pp-13.9 pp
OABIOmniAb, Inc.LTM Mar 2026-117.0% +50.4 pp-225.4 pp
EVMNEvommune, Inc.LTM Mar 2026-746.2% ——
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-3415.1% -3156.5 pp-497.7 pp
CLYMClimb Bio, Inc.FY2025— ——
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
Peer median (excluding EVMN) -28.2%+50.4 pp-39.8 pp

Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5M7M13M
Cost of Revenue1M1.29M0
Gross Profit4M5.71M13M
Gross Margin80.0%81.6%100.0%
Research & Development32M64.24M74.04M
Selling, General & Admin9.85M11.48M20.03M
Operating Expenses41.85M75.73M94.07M
Depreciation & Amortization1M1.29M1.39M
EBITDA(33M)(65.49M)(67.48M)
EBITDA Margin-659.9%-935.5%-519.1%
Operating Income(37.85M)(70.01M)(81.07M)
Operating Margin-757.0%-1000.2%-623.6%
Interest Income3.86M3.24M3.32M
Interest Expense58K34K0
Other Income / Expenses3.8M3.2M12.2M
Income Before Tax(34.05M)(66.81M)(68.87M)
Pre-Tax Margin-681.1%-954.4%-529.8%
Income Tax Expense000
Net Income(34.05M)(66.81M)(68.87M)
Net Margin-681.1%-954.4%-529.8%
EPS (Basic)(1.13)(2.27)(2.18)
EPS (Diluted)(1.13)(2.27)(2.18)
Weighted Avg Shares30.08M30.08M31.52M
Weighted Avg Shares (Diluted)30.08M30.08M31.52M

Evommune, Inc.

NYSE:EVMN

Intrinsic Alpha fair value

Locked

Current Price

$7.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.